The panelists offer their closing remarks regarding immuno-oncology's promises and challenges.
The panelists offer their closing remarks regarding immuno-oncology’s promises and challenges.
Jianda Yuan, MD, PhD, explains why this is an exciting time for immunotherapy, and Kimberly Shafer-Weaver, PhD, added that discussing immuno-oncology early on is important so that the best decisions can be made for not only patients, but also the payers.
“Sometimes, it is tempting, I think, to get discouraged that the innovations that we are seeing are going to come at a price tag that we cannot afford,” Michael Kolodziej, MD, added in conclusion. “I think that is a mistake. I think that what we should be focused on is really finding out how much these innovations truly add to what we are doing now and who benefits the most.”
Covering antiobesity medications like semaglutide could save Medicare around $500 million annually; preliminary CDC data showed a 3% decline in the number of US overdose deaths last year; the Biden administration recently announced the first national maternal mental health strategy.
Read More
After the ACA Expanded Health Care Access, 2024 Elections May See Voters Demand Affordability
May 15th 2024At the spring conference of the New Jersey Health Care Quality Institute, speakers discussed how health policy, affordability, and transparency may play a role in voters’ decisions.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
House lawmakers are expected to advance a contracting ban today on 5 Chinese research firms; US government officials temporarily relaxed strict guidelines on how laboratories handle, store, and transport H5N1 bird flu samples; a recent report found that the number of abortions occurring in the US continued to grow despite bans.
Read More